Caterpillar stock sees AI-driven optimism and strong demand, but slowing growth limits upside. Click here to read an analysis ...

Chipmaker Nvidia ($NVDA) has surged 84% in under four months to briefly reclaim its position as the world’s most valuable ...

Learn everything you need to know about key performance indicators.

Analyst Ratings Published 10/07/2025, 09:30 pm 0 Goldman Sachs resumes Immunovant stock coverage with Neutral rating IMVT -1.75% ...

Additionally, TG Therapeutics presented new data on its multiple sclerosis drug, BRIUMVI, at the Consortium of Multiple Sclerosis Centers meeting, focusing on long-term treatment safety and ...

UBS has maintained its Buy rating with a $60 price target, emphasizing the promising data from CG Oncology’s Cretostimogene, which showed a stable 12-month complete response rate of 46.4% and a longer ...

Investing.com - Goldman Sachs (NYSE: GS) has resumed coverage on Rhythm Pharmaceuticals (NASDAQ: RYTM) with a Buy rating and a price target of $97.00. The stock, currently trading at $89, has shown ...

Investing.com - Goldman Sachs (NYSE:GS) has resumed coverage of Halozyme Therapeutics (NASDAQ:HALO) with a Neutral rating and a $55.00 price target. The company, which has achieved a perfect Piotroski ...

Investing.com - Goldman Sachs resumed coverage on Avidity Biosciences (NASDAQ:RNA) with a Buy rating and a $55.00 price target on Thursday. According to InvestingPro data, this target aligns with ...

Analyst Ratings Published 07/10/2025, 03:12 AM 0 Goldman Sachs resumes Amylyx stock coverage with Buy rating on avexitide potential AMLX 0.00% ...

Antara Dave, a senior product designer, landed her dream job at Microsoft the second time she applied. Here's the resume she used.